
    
      Provides up to six months treatment with CuATSM for subjects who have successffulyl completed
      study CMD-2019-001. [This allows subjects randomized to placebo on study CMD-2019-001 to
      receive up to six months treatment with CuATSM and provides an up to an additional six months
      treatment with CuATSM for subjects randomized to CuATSM on study CMD-2019-001]
    
  